Related Experiment Video
Updated: May 3, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Antimicrobial treatment of serious gram-negative infections in newborns
James W Gray1, Hirminder Ubhi, Philip Milner
1Department of Microbiology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK, Jim.gray@bch.nhs.uk.
Abstract:
The choice of antibiotics for serious Gram-negative bacterial infections in the newborn must balance delivery of effective antibiotics to the site(s) of infection with the need to minimize selection of antibiotic resistance. To reduce the risk of selective pressure from large-scale cephalosporin usage, a penicillin-aminoglycoside combination is recommended as empiric therapy for neonatal sepsis. Where Gram-negative sepsis is strongly suspected or proven, a third-generation cephalosporin should ordinarily replace penicillin. Piperacillin-tazobactam can provide better Gram-negative cover than penicillin-aminoglycoside combinations, without the risk of selecting antibiotic resistance seen with cephalosporins, but further clinical studies are required before this approach to empiric therapy can be recommended. For antibiotic-resistant infections, a carbapenem remains the mainstay of treatment. However, rapid emergence and spread of resistance to these antibiotics means that in the future, neonatologists may have to rely on antibiotics such as colistin, whose pharmacokinetics, safety, and clinical efficacy in neonates are not well-defined.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pharmacokinetics in Pediatric Patients: Drug Excretion
Inhibitors of Bacterial Protein Synthesis
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Development of the Oral Microbiota
Inhibitors of Gram-positive Cell Wall Synthesis

